A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2-locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling

被引：0
|
作者：
LeVee, Alexis Ann
Egelston, Colt A.
Yost, Susan Elaine
Frankel, Paul Henry
Lee, Keehoon
Ruel, Christopher
Schmolze, Daniel
Lee, Peter P.
Yeon, Christina Haeyoung
Yuan, Yuan
Waisman, James Ross
Pal, Sumanta Kumar
Mortimer, Joanne E.
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Translat Genom Res Inst TGen North, Flagstaff, AZ USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1038
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2-early breast cancer
    Mayer, E.
    DeMichele, A.
    Dubsky, P.
    Barry, W.
    Metzger, O.
    Symmans, W. F.
    Burstein, H.
    Miller, K.
    Wolff, A.
    Rastogi, P.
    Loibl, S.
    von Minckwitz, G.
    Goulioti, T.
    Zardavas, D.
    Fesl, C.
    Koehler, M.
    Bartlett, C. Huang
    Chen, L.
    Piccart, M.
    Winer, E.
    Gnant, M.
    CANCER RESEARCH, 2016, 76
  • [22] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [23] Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
    Schmid, Peter
    Sohn, Joo Hyuk
    Jerez Gilarranz, Yolanda
    Gonzalez-Cortijo, Lucia
    Sonnenblick, Amir
    Sabanathan, Dhanusha
    Korbenfeld, Ernesto
    Egle, Daniel
    Poirier, Brigitte
    Zagouri, Flora
    Matikas, Alexios
    Aksoy, Sercan
    Demirci, Umut
    Ramos-Elias, Pier
    Im, Seock-Ah
    Cardoso, Fatima
    Jia, Liyi
    Hirshfield, Kim
    Tryfonidis, Konstantinos
    Rugo, Hope S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 233 - 234
  • [24] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Piudo, Natalia Chavarria
    Blancas, Isabel
    Flores, Encarna Gonzalez
    Carrasco, Fernando Henao
    Alvarez, Pilar Lopez
    Pancorbo, David Morales
    Casado, Salvador Gamez
    Garrido, Maria de la Cabeza Lomas
    Garcia, Jose Manuel Rodriguez
    Guisado, Antonia Martinez
    Vega, Adrian Sanchez
    Borrego, Manuel Ruiz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12): : 3131 - 3141
  • [25] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Chavarria Piudo, Natalia
    Blancas, Isabel
    Gonzalez Flores, Encarnacion
    Henao Carrasco, Fernando
    Lopez Alvarez, Pilar
    Morales Pancorbo, David
    Baena-Canada, Jose Manuel
    Lomas Garrido, Maria de la Cabeza
    Rodriguez, Jose Manuel
    Martinez Guisado, Antonia
    Sanchez Vega, Adrian
    Ruiz-Borrego, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial
    Safra, Tamar
    Kaufman, Bella
    Kadouri, Luna
    Efrat , Noa
    Ryvo, Larisa
    Nisenbaum, Bella
    Evron, Ella
    Yerushalmi, Rinat
    CLINICAL BREAST CANCER, 2018, 18 (02) : E197 - E203
  • [27] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [28] Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
    Rugo, Hope S.
    Turner, Nicholas C.
    Finn, Richard S.
    Joy, Anil A.
    Verma, Sunil
    Harbeck, Nadia
    Masuda, Norikazu
    Im, Seock-Ah
    Huang, Xin
    Kim, Sindy
    Sun, Wan
    Iyer, Shrividya
    Schnell, Patrick
    Bartlett, Cynthia Huang
    Johnston, Stephen
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 123 - 133
  • [29] Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/ HER2-breast cancer in Germany: Interim results of the INGE-B phase II study
    Welslau, M. K.
    Zaiss, M.
    Soeling, U.
    Untch, M.
    Mueller, L.
    Lueftner, D.
    Meiler, J.
    Welt, A.
    Sahlmann, J.
    Houet, L.
    Runkel, E.
    Marschner, N. W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
    Dieras, Veronique
    Rugo, Hope S.
    Schnell, Patrick
    Gelmon, Karen
    Cristofanilli, Massimo
    Loi, Sherene
    Colleoni, Marco
    Lu, Dongrui R.
    Mori, Ave
    Gauthier, Eric
    Huang Bartlett, Cynthia
    Slamon, Dennis J.
    Turner, Nicholas C.
    Finn, Richard S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (04): : 419 - 430
12345